Babson Diagnostics offers a blood testing service that utilizes a fingerstick method to collect a small volume of blood, providing accurate diagnostic results at retail pharmacies. This approach addresses the inconvenience and accessibility issues associated with traditional blood testing, enabling patients to obtain essential health insights more easily.
Funding
$44.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional blood testing methods often require venipuncture, which can be inconvenient, painful, and inaccessible for some patients. This can lead to delayed or avoided testing, hindering timely diagnosis and monitoring of health conditions.
Solution
Babson Diagnostics offers a blood testing service called BetterWay that utilizes a fingerstick method to collect a small, pea-sized volume of blood, providing accurate diagnostic results at retail pharmacies and accessible care settings. This approach aims to make routine blood testing less invasive, more convenient, and more affordable, empowering individuals to proactively manage their health. The company's patented technologies and ecosystem require only one-tenth the sample volume of traditional venipuncture methods without sacrificing quality, accuracy, or the selection of available tests. Clinically validated by rigorous studies, BetterWay technology delivers innovation and accuracy.
Target Audience
The primary target audience includes patients who seek convenient and less invasive blood testing options, clinicians looking to improve patient access and adherence to testing, and retailers and payers aiming to offer accessible and cost-effective healthcare solutions.
Features
- Fingerstick blood collection requiring only a pea-sized blood sample
- Medically accurate results comparable to traditional venipuncture
- Testing available at retail pharmacies and other accessible care settings
- Patented technologies enabling reduced sample volume without compromising test quality
- Clinically validated through rigorous studies